KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$9.46 USD
-0.19 (-1.97%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $9.46 0.00 (0.00%) 4:32 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 1 - 20 ( 107 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our Thoughts on HAE Market Ahead of Potential FDA Approval and Launch of Sebetralstat 1H25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sebetralstat NDA Submission Catalyst Expected June 2024 - Deprioritizing Factor XIIa; Reducing PT to $20, Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
First Oral On-Demand HAE Therapy on Horizon-Looking to NDA Expected 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sebetralstat Delivers Positive On-Demand HAE Profile-Raising PT to $24; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
On-Demand HAE Oral Optionality Phase 3 KONFIDENT Topline Expected Early 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for KALV 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Near-Term 4Q23 Sebetralstat Readout From Phase 3 KONFIDENT Trial; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sebetralstat Progress With Phase 3 KONFIDENT Readout Expected 4Q23; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Sebetralstat Confidence-Looking to Phase 3 KONFIDENT Trial 2H23; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Turning a New Page for Sebetralstat-Looking to Phase 3 Data 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Shifting Focus to On-Demand Sebetralstat, Distinction From KVD824; PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Plasma Kallikrein Inhibitor Platform Progress-Looking to Data in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Oral HAE On-Demand and Prophylaxis Progress, With Factor XIIa Inhibitor Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY3Q22 - Enrollment Progress in HAE in 2022 Tees Up Key Readouts in 2023
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
KVD900 and KVD824-Two Shots on Goal for Oral HAE Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A